옵션 체인은 다양한 행사가격과 만기일에 대한 Citius Pharmaceuticals의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Citius Pharmaceuticals에 대한 시장 심리를 평가합니다..

Citius Pharmaceuticals (NASDAQ:CTXR) 주식, 옵션 체인

CITIUS PHARMACEUTICALS INC

Citius Pharma

Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. The company is currently advancing four proprietary product candidates namely, LYMPHIR for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections, Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries, Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids, and others.

Things To Keep In Mind While Gifting Stocks

News

Pre-Market Outlook

Markets

Trading Ideas

$LUNA

CCTG

CTXR

LUNA

월요일(30일) 아침 미국 주식 선물이 하락한 가운데, 오늘 투자자들의 관심을 끌 수 있는 종목은 다음과 같다. 셀 사이, CCSC 테크놀로지, 루나 이노베이션스, 시티우스 파마슈티컬스 및 지니어스 그룹

월요일 주목해야 할 주식: 셀 사이, CCSC 테크놀로지, 루나 이노베이션스, 시티우스 및 지니어스 그룹

Citius Pharmaceuticals, Inc. - Common Stock

Citius Pharmaceuticals Inc

Benchmark analyst David Williams reiterates Lattice Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSCC#NASDAQ">LSCC</a>) with a Buy and maintains $60 price target.

Price Target

Reiteration

Analyst Ratings

LSCC

Benchmark Reiterates Buy on Lattice Semiconductor, Maintains $60 Price Target

WIIM

LMND

Lemonade shares are trading higher after the company reported better-than-expected Q1 financial results and raised its FY25 sales guidance above estimates.

The Oracle of Omaha, Warren Buffett, during the 2025 Berkshire Hathaway Annual Meeting, expressed his disappointment over the depreciating U.S. dollar and said that no one would want to hold assets in a currency that was falling in value.
What Happened: Talking about the U.S. dollar, Buffett said, &#8220;You wouldn&#8217;t want to be owning anything that we thought was in a currency that was really going to hell. And that&#8217;s the biggest thing we are worried about United States currency.&#8221;
&#8220;I mean, the tendency of our government to want to debase its currency over time, there is no system that beats that,&#8221; he added, criticizing the government&#8217;s stance on a weaker dollar.
Buffett also underscored his concerns about the fiscal policy.
&#8220;You can pick dictators, you can pick representatives, you can do anything. But there will be a push toward a weaker currency. And of course, fiscal policy is what scares me in the United States because it&#8217;s made the way it is,&#8221; said Buffett.
See Also: <a href="https://www.benzinga.com/25/05/45213790/us-dollar-depreciation-is-cushioning-the-impact-of-tariffs-on-corporate-profits-says-expert-heres-how">US Dollar Depreciation Is Cushioning &#8216;The Impact Of Tariffs On Corporate Profits,&#8217; Says Expert</a>
Why It Matters: Analysts have criticized the U.S. government&#8217;s attempt to <a href="https://www.benzinga.com/government/regulations/25/04/44858165/policy-push-vs-market-pull-dollar-under-pressure-as-reserve-curren">weaken the U.S. dollar</a> in their analyses. Commentary from Chatham House expert David Lubin pointed out a "view of some within the Trump administration that the reserve currency status of the dollar is more of a burden to the U.S. economy than a blessing." 
According to him, the government&#8217;s &#8220;policy push" aims to weaken the dollar permanently against other currencies, hoping to reduce the trade deficit and attract manufacturers to the U.S.
However, Lubin strongly cautions against this approach, arguing that "if the international monetary system cannot rely on the dollar&#8217;s full convertibility, or its availability in a crisis, it is entering unknown territory. Undermining the dollar&#8217;s global status would not only transmit huge amounts of additional uncertainty to the global economy, but would be a needless act of self-harm for the U.S."
Price Action: As of the publication of this article, the U.S. Dollar Index Spot was 0.11% lower at the 99.7200 level. It has fallen by 8.02% on a year-to-date basis.
Whereas, the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, fell on Monday. The SPY was down 0.57% to $563.51, while the QQQ declined 0.59% to $485.93, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
In premarket on Tuesday, SPY declined 0.61% and QQQ was down 0.84%.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/05/45214653/uber-could-win-the-robo-taxi-war-says-expert-analyst-predicts-75-gains-on-ride-hailing-cost-drop">Uber Could Win The &#8216;Robo Taxi War,&#8217; Says Expert: Analyst Predicts 75% Gains On Ride Hailing Cost Drop</a></li>
</ul>
Photo courtesy: mark reinstein / Shutterstock.com

Equities

Macro Economic Events

Market Summary

Broad U.S. Equity ETFs

Futures

Forex

Economics

ETFs

General

Warren Buffett Expresses Disappointment Over Dollar Depreciation: Don't Want To Own Assets In A Currency That Is 'Really Going To Hell'

<ul>
<li>Results from studies at Virginia Commonwealth University (VCU) show that an Aramchol and Bayer's Regorafenib drug combination significantly reduced hepatic tumor growth in mice models.</li>
<li>The cell killing effect in-vitro and in-vivo was due to increased autophagy and death receptor signaling.</li>
<li>A Phase 1b Study of the addition of Aramchol to Regorafenib in patients with advanced GI cancers is planned to be initiated at VCU's Massey Cancer Center in Q4 2025.</li>
<li>Leveraging on its long-standing experience in liver and metabolic diseases, Galmed plans to advance the novel combination oncology program in parallel to the recently announced Semaglutide GLP-1 development.</li>
</ul>
TEL AVIV, Israel, May 6, 2025 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLMD#NASDAQ">GLMD</a>) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for cardiometabolic diseases and GI oncological therapeutics, announced today that the first set of oncology studies has shown that Aramchol enhances the liver / colorectal cancer-approved therapeutic Regorafenib effects in liver and colon cancers in-vitro and in-vivo models.

GLMD

Galmed Pharma: First Set Of Oncology Studies Show Aramchol Enhances Liver / Colorectal Cancer-approved Therapeutic Regorafenib Effects In Liver And Colon Cancers In-vitro And In-vivo Models

Clorox shares are trading lower after the company reported worse-than-expected Q3 financial results and narrowed its FY25 sales guidance below estimates.

Canaccord Genuity analyst Sumant Kulkarni maintains Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) with a Buy and raises the price target from $158 to $160.

NBIX

Canaccord Genuity Maintains Buy on Neurocrine Biosciences, Raises Price Target to $160

Benchmark analyst David Williams maintains ON Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ON#NASDAQ">ON</a>) with a Buy and lowers the price target from $60 to $50.

Benchmark Maintains Buy on ON Semiconductor, Lowers Price Target to $50

AngloGold Ashanti shares are trading higher. The company paused its discussions about its joint venture with Gold Fields to focus on improving their standalone performance at their respective sites.

Madison Square Garden (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSGE#NYSE">MSGE</a>) reported quarterly earnings of $0.17 per share which missed the analyst consensus estimate of $0.23 by 26.09 percent. This is a 183.33 percent increase over earnings of $0.06 per share from the same period last year. The company reported quarterly sales of $242.47 million which beat the analyst consensus estimate of $231.13 million by 4.90 percent. This is a 6.20 percent increase over sales of $228.31 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

MSGE

Madison Square Garden Q3 EPS $0.17 Misses $0.23 Estimate, Sales $242.47M Beat $231.13M Estimate

Intercontinental Exchange, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ICE#NYSE">ICE</a>), a leading global provider of technology and data, and OPEN, a pioneer in private market indexing, today announced the launch of the NYSE&#xAE; OPEN VC Unicorn&#xAE; 20 Index (NYOV20L), a new benchmark designed to track the performance of 20 of the largest U.S.-based, privately held, venture-backed Unicorn companies.
This new index expands upon the success of the NYSE&#xAE; OPEN Venture Capital Unicorn&#xAE; Index (NYSEOVC) by offering a focused, liquidity-screened basket of the highest-valued private companies. The NYSE&#xAE; OPEN VC Unicorn&#xAE; 20 Index aims to provide investors with enhanced transparency into the largest and most dynamic companies driving innovation across sectors such as artificial intelligence, technology, fintech and aerospace.

ICE and OPEN Launch NYSE Unicorn 20 Index to Track America's Biggest Private Tech Giants

<ul>
<li>CorMedix expects to be at the high-end of the previously announced first half net sales guidance of $62 million to $70 million, based on latest order trends and inventory tracking with current purchasing customers.</li>
</ul>

Guidance

CRMD

Cormedix Expects To Be At High-End Of Previously Announced 1H Net Sales Guidance Of $62M-$70M

Canaccord Genuity analyst Brian McNamara maintains EZCORP (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EZPW#NASDAQ">EZPW</a>) with a Buy and lowers the price target from $25 to $24.

EZPW

Canaccord Genuity Maintains Buy on EZCORP, Lowers Price Target to $24

Koninklijke Philips shares are trading lower after the company reported Q1 financial results and trimmed its adjusted EBITA margin. Also, the company reported a year-over-year decrease in comparable sales.

Ranpak Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PACK#NYSE">PACK</a>) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.09) by 44.44 percent. This is a 30 percent decrease over losses of $(0.10) per share from the same period last year. The company reported quarterly sales of $91.20 million which beat the analyst consensus estimate of $90.56 million by 0.71 percent. This is a 6.92 percent increase over sales of $85.30 million the same period last year.

PACK

Ranpak Hldgs Q1 EPS $(0.13) Misses $(0.09) Estimate, Sales $91.20M Beat $90.56M Estimate

SUUN

SolarBank Corporation Says CIM Group Entered Into Mandate Letter Providing For Up To $100M In Project Based Financing For Portfolio Of 97 MW Of Solar Power Projects In U.S.

Caliber Enters Development Rights Agreement With An Affiliate Of Hyatt To Develop 15 New Hyatt Studios Hotels In The United States

Needham analyst Kyle Peterson initiates coverage on Broadridge Financial Soln (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BR#NYSE">BR</a>) with a Buy rating and announces Price Target of $300.

Initiation

Needham Initiates Coverage On Broadridge Financial Soln with Buy Rating, Announces Price Target of $300

Ballard Power Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLDP#NASDAQ">BLDP</a>) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.10) by 30 percent. This is a 50 percent increase over losses of $(0.14) per share from the same period last year. The company reported quarterly sales of $15.40 million which missed the analyst consensus estimate of $16.68 million by 7.65 percent. This is a 6.21 percent increase over sales of $14.50 million the same period last year.

BLDP

Ballard Power Systems Q1 EPS $(0.07) Beats $(0.10) Estimate, Sales $15.40M Miss $16.68M Estimate

Ballard Power Systems (TSX:<a class="ticker" href="https://www.benzinga.com/stock/BLDP#TSX">BLDP</a>) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.11) by 36.36 percent. This is a 50 percent increase over losses of $(0.14) per share from the same period last year. The company reported quarterly sales of $15.40 million which missed the analyst consensus estimate of $16.73 million by 7.95 percent. This is a 6.21 percent increase over sales of $14.50 million the same period last year.

TSX:BLDP

Ballard Power Systems Q1 EPS $(0.07) Beats $(0.11) Estimate, Sales $15.40M Miss $16.73M Estimate

Cormedix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRMD#NASDAQ">CRMD</a>) reported quarterly earnings of $0.30 per share which beat the analyst consensus estimate of $0.24 by 25 percent. This is a 220 percent increase over losses of $(0.25) per share from the same period last year. The company reported quarterly sales of $39.08 million which beat the analyst consensus estimate of $36.00 million by 8.55 percent.

Cormedix Q1 EPS $0.30 Beats $0.24 Estimate, Sales $39.08M Beat $36.00M Estimate

Stock Split

Press Releases

Citius Pharmaceuticals, Inc. Announces 1-for-25 Reverse Stock Split

Citius Pharmaceuticals Reports Productive FDA Type C Meeting to Discuss Phase 3 Mino-Lok® Program and Pathway to Approval

Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update

Small Cap

Citius Oncology Engages Jefferies as Exclusive Financial Advisor to Explore Strategic Alternatives

Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025

Offerings

Citius Pharmaceuticals Announces $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

Contracts

Citius Pharmaceuticals and Citius Oncology Announce Unique Permanent J-Code Issued for LYMPHIR by Centers for Medicare and Medicaid Services

Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update

Citius Pharmaceuticals Announces $2 Million Registered Direct Offering of Common Stock

Citius Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

CTOR

Adial Pharmaceuticals, Inc - Common Stock

Adial Pharmaceuticals

Addex Therapeutics Ltd - American Depositary Shares

Addex Therapeutics

Athira Pharma

Aytu BioPharma

Biofrontera

Cingulate

Cocrystal Pharma

Citius Pharmaceuticals

Evoke Pharma

Gelteq

Hoth Therapeutics

Impact BioMedical

Jaguar Health

Kiora Pharmaceuticals, Inc. - Common Stock

Kiora Pharmaceuticals

Lyra Therapeutics

Purple Biotech Ltd. - American Depositary Shares

Purple Biotech

ProPhase Labs

Petros Pharmaceuticals, Inc. - Common Stock

Petros Pharma

Redhill Biopharma Ltd. - American Depositary Shares

Redhill Biopharma

Relmada Therapeutics, Inc. - Common Stock

Relmada Therapeutics

SenesTech

Sonoma Pharmaceuticals, Inc. - Common Stock

Sonoma Pharmaceuticals

60 Degrees Pharmaceuticals, Inc. - Common Stock

60 Degrees

Talphera

Traws Pharma

Titan Pharmaceuticals, Inc. - Common Stock

Titan Pharma

D. Boral Capital

HC Wainwright & Co.

EF Hutton

Screenshot 2024-08-06 at 7.17.40 PM

Biotech

TENK

Citius Pharmaceuticals To Receive 65 Million Shares Of TenX Keane For Merger Of Citius Oncology

Screenshot 2024-07-29 at 8.39.42 PM

From fighting cancer to treating bloodstream infections, Citius Pharmaceuticals Inc. (NASDAQ:CTXR) is busy trying to solve some of the world&#39;s ills. That&#39;s picking up steam with two of its lead products close to commercialization. 

Citius Pharmaceuticals Nears Market Breakthrough With Two Leading Products

Screenshot 2024-07-24 at 5.43.01 PM

Interview

This Pharma Company Is Preparing To Launch Its Lead Candidate

Screenshot 2024-04-17 at 5.34.28 PM

Citius Pharmaceuticals (NASDAQ: CTXR) Advances Oncology Asset, Paving Way For Spin Out Of Advanced T-cell Lymphoma Treatment

Comments

Citius Pharmaceuticals

Citius Pharmaceuticals (CTXR) 옵션

Citius Pharmaceuticals (NASDAQ:CTXR) 주식, 옵션 체인

뉴스

파트너 / 기고자

벤징가 글로벌